Home
TARS
TARS News

Latest Tarsus Pharmaceuticals Inc. (TARS) News on April 19, 2025

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 03/24/2025

MT Newswires

a month ago

Tarsus Pharmaceuticals Insider Sold Shares Worth $1,163,050, According to a Recent SEC Filing

MT Newswires

a month ago

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires

a month ago

Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

GlobeNewswire

a month ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Tarsus Announces Proposed $100.0 Million Public Offering

GlobeNewswire

a month ago

Tarsus Announces Proposed $100.0 Million Public Offering

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire

a month ago

Tarsus to Participate in Upcoming Investor Conference

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call

Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com

2 months ago

Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

2 months ago

Tarsus Pharmaceuticals Q4 Loss Narrows, Revenue Rises

Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

GlobeNewswire

2 months ago

Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For

GuruFocus.com

2 months ago

Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

GlobeNewswire

2 months ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Simply Wall St.

2 months ago

Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

MT Newswires

3 months ago

BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Tarsus to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?

Zacks

3 months ago

CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?

MT Newswires

3 months ago

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating

Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Insider Monkey

3 months ago

Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround

Zacks

3 months ago

Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

GlobeNewswire

3 months ago

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

Zacks

3 months ago

Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run

Investor's Business Daily

4 months ago

How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

Zacks

4 months ago

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Zacks

4 months ago

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet

Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade

Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

MT Newswires

5 months ago

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...

GuruFocus.com

5 months ago

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

5 months ago

Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

GlobeNewswire

5 months ago

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

GlobeNewswire

5 months ago

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

5 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

GlobeNewswire

5 months ago

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

GlobeNewswire

5 months ago

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?

Zacks

6 months ago

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?

Zacks

6 months ago

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

GlobeNewswire

6 months ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...

GuruFocus.com

6 months ago

Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

GlobeNewswire

7 months ago

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

GlobeNewswire

8 months ago

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

Simply Wall St.

8 months ago

Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

MT Newswires

8 months ago

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

GlobeNewswire

8 months ago

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

GlobeNewswire

9 months ago

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

Simply Wall St.

9 months ago

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

10 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Business Wire

10 months ago

Form 8.3 - Darktrace plc

Business Wire

10 months ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

10 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

10 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

10 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

GlobeNewswire

10 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

Business Wire

10 months ago

Form 8.3 - International Paper Company

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Tarsus to Participate in Upcoming Investor Conferences

Earnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.

a year ago

Earnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their Estimates

Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

GlobeNewswire

a year ago

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript

MT Newswires

a year ago

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating

GuruFocus.com

a year ago

Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

GlobeNewswire

a year ago

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?

Zacks

a year ago

Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

GlobeNewswire

a year ago

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

GlobeNewswire

a year ago

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%

Simply Wall St.

a year ago

Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%

Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know

Aggressive Stock Portfolio: 13 Stocks Picked by Analysts

Insider Monkey

a year ago

Aggressive Stock Portfolio: 13 Stocks Picked by Analysts

Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why

Zacks

a year ago

Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

Zacks

a year ago

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

Tarsus to Participate at Upcoming Investor Conferences

GlobeNewswire

a year ago

Tarsus to Participate at Upcoming Investor Conferences

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

GlobeNewswire

a year ago

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

a year ago

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Tarsus Announces Pricing of $100.0 Million Public Offering

GlobeNewswire

a year ago

Tarsus Announces Pricing of $100.0 Million Public Offering

Tarsus Announces Proposed $100.0 Million Public Offering

GlobeNewswire

a year ago

Tarsus Announces Proposed $100.0 Million Public Offering

Party Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings Forecasts

Simply Wall St.

a year ago

Party Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings Forecasts

Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy

Zacks

a year ago

Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript

Tarsus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

a year ago

Tarsus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Thomson Reuters StreetEvents

a year ago

Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call

Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results

GuruFocus.com

a year ago

Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

GlobeNewswire

a year ago

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

GlobeNewswire

a year ago

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

GlobeNewswire

a year ago

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Lemonade (LMND) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

a year ago

Lemonade (LMND) Stock Drops Despite Market Gains: Important Facts to Note

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

Simply Wall St.

a year ago

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

GlobeNewswire

a year ago

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

Zacks

a year ago

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

Why Zim Integrated Shipping Stock Is Cruising Higher Today

Motley Fool

a year ago

Why Zim Integrated Shipping Stock Is Cruising Higher Today

Unpacking Q3 Earnings: USANA (NYSE:USNA) In The Context Of Other Personal Care Stocks

StockStory

a year ago

Unpacking Q3 Earnings: USANA (NYSE:USNA) In The Context Of Other Personal Care Stocks

First Citizens BancShares, Inc. (NASDAQ:FCNCA) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

First Citizens BancShares, Inc. (NASDAQ:FCNCA) Q4 2023 Earnings Call Transcript

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

83% of Warren Buffett's $365 Billion Portfolio Is Invested in Just 7 Stocks

Motley Fool

a year ago

83% of Warren Buffett's $365 Billion Portfolio Is Invested in Just 7 Stocks

Reuters

a year ago

GLOBAL MARKETS-Asia stocks eye weekly gain; US inflation data looms

Share on Social Networks: